Using AI-designed proteins to improve the creation of insulin-producing cells from stem cells.
AI-guided miniproteins driving the production and functional endurance of pancreatic islet tissue from pluripotent stem cells.
This study is exploring a new way to create healthy insulin-producing cells from stem cells, using special mini-proteins to help the cells grow better, which could lead to improved treatments for diabetes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10976994 on NIH RePORTER |
What this research studies
This research focuses on enhancing the production of functional pancreatic islet cells, which are crucial for insulin production, from pluripotent stem cells. By utilizing AI-designed mini-proteins known as EpiBinders, the project aims to improve the efficiency of cell differentiation processes. These mini-proteins work by modifying gene expression to promote the development of mature islet cells, potentially leading to better outcomes for diabetes treatment. The research team combines expertise in stem cell biology and artificial intelligence to tackle the challenges of current differentiation protocols.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with diabetes who may benefit from advanced cell replacement therapies.
Not a fit: Patients who do not have diabetes or those whose diabetes is not amenable to cell replacement therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for diabetes by providing a reliable source of insulin-producing cells.
How similar studies have performed: Previous research has shown promise in using similar approaches to enhance stem cell differentiation, indicating potential for success in this novel application.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Cirulli, Vincenzino — University of Washington
- Study coordinator: Cirulli, Vincenzino
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.